Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case-Control Study in the Department of Defense Serum Repository.
We previously identified associations of esophageal adenocarcinoma risk with four inflammation-related candidate biomarkers: TNF receptor 2 (TNFR2), IL17A, VEGFR3, and resistin. We aimed to replicate these candidates and discover novel associations with additional proteins. We conducted a nested case-control study of men with prediagnostic biospecimens stored at the US Department of Defense Serum Repository, including 203 incident esophageal adenocarcinoma cases. Controls were matched to cases in a ∼2:1 ratio by date of birth, race, service branch, and blood draw date. Multiplex immunoassays (Olink/Proseek panels) measured 254 proteins detected in ≥10% of all samples. Multivariable-adjusted conditional logistic regression models calculated associations between biomarker quantiles and esophageal adenocarcinoma. P values (<0.05) were used to indicate the statistical significance of candidates, and FDR was applied to the additional proteins. ORs from the current analysis and those from previous studies were combined for the candidate markers using fixed-effects meta-analysis. Among the four candidates, the highest category of TNFR2 was associated with significantly increased esophageal adenocarcinoma risk (ORQ4 vs. Q1 = 1.87; 95% confidence interval: 1.02-3.42). In the meta-analysis, associations with esophageal adenocarcinoma were positive for TNFR2 (meta-analyzed ORhighest-vs.-lowest = 2.04; 1.12-2.95) and inverse for IL17A (meta-analyzed ORhighest-vs.-lowest = 0.53; 0.26-0.80). Of the additional 250 proteins, 45 were associated with esophageal adenocarcinoma risk and 6 (monocyte chemotactic protein 3, IL6, TNFR1, hepatocyte growth factor, TFF3, and FURIN) remained significant after FDR correction. We confirmed associations of TNFR2 and IL17A with esophageal adenocarcinoma risk. Additionally, our study expands the range of proteins associated with esophageal adenocarcinoma development. This is the largest assessment to discover novel associations of inflammation-related proteins with esophageal adenocarcinoma to date.
36
- 10.1002/cncr.30365
- Nov 8, 2016
- Cancer
6
- 10.1038/srep15340
- Oct 22, 2015
- Scientific Reports
94
- 10.1186/1471-2407-14-103
- Feb 18, 2014
- BMC Cancer
296
- 10.4049/jimmunol.180.10.6467
- May 3, 2008
- Journal of immunology (Baltimore, Md. : 1950)
28
- 10.1038/ajg.2014.324
- Oct 21, 2014
- American Journal of Gastroenterology
262
- 10.1002/gepi.20422
- Mar 30, 2009
- Genetic epidemiology
46
- 10.1016/j.coph.2009.09.005
- Oct 12, 2009
- Current Opinion in Pharmacology
23
- 10.1097/md.0000000000000860
- May 1, 2015
- Medicine
73
- 10.1152/ajpgi.00458.2010
- Dec 9, 2010
- American Journal of Physiology-Gastrointestinal and Liver Physiology
52
- 10.1002/oby.20060
- Mar 1, 2013
- Obesity
- Preprint Article
- 10.1158/1055-9965.c.7799064
- May 2, 2025
<div>AbstractBackground:<p>We previously identified associations of esophageal adenocarcinoma risk with four inflammation-related candidate biomarkers: TNF receptor 2 (TNFR2), IL17A, VEGFR3, and resistin.</p>Methods:<p>We aimed to replicate these candidates and discover novel associations with additional proteins. We conducted a nested case–control study of men with prediagnostic biospecimens stored at the US Department of Defense Serum Repository, including 203 incident esophageal adenocarcinoma cases. Controls were matched to cases in a ∼2:1 ratio by date of birth, race, service branch, and blood draw date. Multiplex immunoassays (Olink/Proseek panels) measured 254 proteins detected in ≥10% of all samples. Multivariable-adjusted conditional logistic regression models calculated associations between biomarker quantiles and esophageal adenocarcinoma. <i>P</i> values (<0.05) were used to indicate the statistical significance of candidates, and FDR was applied to the additional proteins. ORs from the current analysis and those from previous studies were combined for the candidate markers using fixed-effects meta-analysis.</p>Results:<p>Among the four candidates, the highest category of TNFR2 was associated with significantly increased esophageal adenocarcinoma risk (OR<sub>Q4 vs. Q1</sub> = 1.87; 95% confidence interval: 1.02–3.42). In the meta-analysis, associations with esophageal adenocarcinoma were positive for TNFR2 (meta-analyzed OR<sub>highest-vs.-lowest</sub> = 2.04; 1.12–2.95) and inverse for IL17A (meta-analyzed OR<sub>highest-vs.-lowest</sub> = 0.53; 0.26–0.80). Of the additional 250 proteins, 45 were associated with esophageal adenocarcinoma risk and 6 (monocyte chemotactic protein 3, IL6, TNFR1, hepatocyte growth factor, TFF3, and FURIN) remained significant after FDR correction.</p>Conclusions:<p>We confirmed associations of TNFR2 and IL17A with esophageal adenocarcinoma risk. Additionally, our study expands the range of proteins associated with esophageal adenocarcinoma development.</p>Impact:<p>This is the largest assessment to discover novel associations of inflammation-related proteins with esophageal adenocarcinoma to date.</p></div>
- Discussion
- 10.1016/j.cgh.2014.08.006
- Aug 13, 2014
- Clinical Gastroenterology and Hepatology
Issue Highlights
- Research Article
74
- 10.1053/j.gastro.2010.01.004
- Jan 18, 2010
- Gastroenterology
The Risk of Esophageal Adenocarcinoma After Antireflux Surgery
- Preprint Article
- 10.1158/1055-9965.28918716
- May 2, 2025
<p>Supplementary Table 2. Associations between replicated biomarkers and esophageal adenocarcinoma risk in the Department of Defense Serum Repository, restricting to matched pairs with cases diagnosed ≥5 and ≥10 years after blood draw.</p>
- Research Article
61
- 10.1002/cncr.21229
- Jun 21, 2005
- Cancer
To investigate individual susceptibility to gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma, the authors studied the frequency of the common G870A polymorphism of CCND1, which encodes cyclin D1, a key cell cycle regulatory protein. The study population included 307 patients who were enrolled in a prospective case-control study to evaluate lifestyle risk factors and molecular alterations in gastroesophageal reflux disease (n = 126 patients), Barrett esophagus (n = 125 patients), and esophageal adenocarcinoma (n = 56 patients). A control group included 95 strictly asymptomatic individuals. Genomic DNA was extracted from cases and controls, and polymerase chain reaction was used to amplify exon 4 of CCND1. After digestion with BsrI, acrylamide gel electrophoresis was used to identify the wild type and common G870A polymorphic alleles. The frequency of alleles (G/G, G/A, A/A) was compared between cases and controls. Immunohistochemistry was used to study cyclin D1 distribution in among patients in the case group. Compared with the asymptomatic control group, and adjusted for age and gender, increasing frequencies were seen for the A/A genotype in patients with gastroesophageal reflux disease (odds ratio [OR], 2.83; 95% confidence interval [95% CI], 1.09-7.34), Barrett esophagus (OR, 3.69; 95% CI, 1.46-9.29), and esophageal adenocarcinoma (OR, 5.99; 95% CI, 1.86-18.96). No association was seen between genotype and cyclin D1 overexpression. The CCND1 A/A genotype was associated with increased risk for gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. The contribution of this polymorphism to susceptibility of defined stages of progression to esophageal adenocarcinoma suggested potential application in endoscopic Barrett surveillance programs.
- Research Article
- 10.1200/jco.2009.27.15_suppl.11029
- May 20, 2009
- Journal of Clinical Oncology
11029 Background: Single nucleotide polymorphisms (SNPs) of key cancer genes, such as EGF A61G, are associated with an elevated risk of EAC, but the lack of full penetrance indicates that the effects of these SNPs on esophageal carcinogenesis are modified by additional genetic or environmental variables. Since GERD is an established risk factor for EAC, we evaluated whether the association between EGF polymorphism and EAC development is altered by the presence of GERD. Methods: EGF genotyping of DNA samples was performed and GERD history was collected for 309 EAC patients and 275 matched healthy controls. Associations between genotypes and EAC risk were examined with adjusted logistic regression. Genotype-GERD relationships were explored using analyses stratified by GERD history and joint effects models that considered severity and duration of GERD symptoms. Results: Baseline characteristics were comparable between cases and controls except that EGF variants (A/G or G/G) were more common (p=0.02) and GERD was more prevalent (p<0.001) in cases than in controls. When compared to the EGF wild type A/A genotype, the G/G variant was associated with an increased risk of EAC (OR 1.9; 95% CI, 1.2–3.0; p=0.007). Stratified analyses revealed that the G/G variant contributed to a substantial increase in EAC risk among individuals with GERD, but a slight decrease in risk for GERD-free individuals (see table). In the joint effects models, the odds of EAC was also highest for G/G patients who either experienced frequent GERD of more than once per week (OR 21.8; 95% CI, 5.1–94.0; p<0.001) or suffered GERD for longer than 15 years (OR 22.4; 95% CI, 6.5–77.6; p<0.001). There was a highly significant interaction between the G/G genotype and the presence of GERD (p<0.001). Conclusions: EGF A61G polymorphism exerts its effect on EAC susceptibility through an interaction with GERD. Performing EGF genotyping for patients with severe or longstanding GERD can help to identify individuals at the greatest risk of EAC. [Table: see text] No significant financial relationships to disclose.
- Research Article
23
- 10.1007/s12029-011-9322-9
- Sep 27, 2011
- Journal of Gastrointestinal Cancer
Polymorphisms in the vitamin D receptor (VDR) gene may be of etiological importance in determining cancer risk. The aim of this study was to assess the association between common VDR gene polymorphisms and esophageal adenocarcinoma (EAC) risk in an all-Ireland population-based case-control study. EAC cases and frequency-matched controls by age and gender recruited between March 2002 and December 2004 throughout Ireland were included. Participants were interviewed, and a blood sample collected for DNA extraction. Twenty-seven single nucleotide polymorphisms in the VDR gene were genotyped using Sequenom or TaqMan assays while the poly(A) microsatellite was genotyped by fluorescent fragment analysis. Unconditional logistic regression was applied to assess the association between VDR polymorphisms and EAC risk. A total of 224 cases of EAC and 256 controls were involved in analyses. After adjustment for potential confounders, TT homozygotes at rs2238139 and rs2107301 had significantly reduced risks of EAC compared with CC homozygotes. In contrast, SS alleles of the poly(A) microsatellite had significantly elevated risks of EAC compared with SL/LL alleles. However, following permutation analyses to adjust for multiple comparisons, no significant associations were observed between any VDR gene polymorphism and EAC risk. VDR gene polymorphisms were not significantly associated with EAC development in this Irish population. Confirmation is required from larger studies.
- Research Article
10
- 10.1002/ijc.29863
- Oct 5, 2015
- International journal of cancer
The strong male predominance in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) remains inadequately explained, but sex hormones might be involved. We hypothesized that single nucleotide polymorphisms (SNPs) in the androgen pathway influence risk of developing BE and EAC. This genetic-epidemiological analysis included 14 studies from Australia, Europe and North America. Polymorphisms in 16 genes coding for the androgen pathway were analyzed using a gene-based approach: versatile gene-based test association study. This method evaluates associations between a trait and all SNPs within a specific gene rather than each SNP marker individually as in a conventional GWAS. The data were stratified for sex, body-mass index, waist-to-hip ratio, tobacco smoking and gastroesophageal reflux status. Included were data from 1,508 EAC patients, 2,383 BE patients and 2,170 control participants. SNPs within the gene CYP17A1 were associated with risk of BE in the sexes combined (p = 0.002) and in males (p = 0.003), but not in females separately (p = 0.3). This association was found in tobacco smokers (p = 0.003) and in BE patients without reflux (p = 0.004), but not in nonsmokers (p = 0.2) or those with reflux (p = 0.036). SNPs within JMJD1C were associated with risk of EAC in females (p = 0.001). However, none of these associations replicated in a subsequent sample. Fourteen other genes studied did not reach statistically significant levels of association with BE, EAC or the combination of BE and EAC, after correcting for the number of genes included in the analysis. In conclusion, genetic variants in the androgen-related genes CYP17A1 and JMJD1C might be associated with risk of BE and EAC, respectively, but replication data with larger sample sizes are needed.
- Research Article
- 10.1158/1940-6207.prev-09-a113
- Jan 7, 2010
- Cancer Prevention Research
Purpose: Selenium may protect against the development of esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA). Only in very few studies have the associations with ESCC and GCA been investigated, and no epidemiologic studies exist on EAC. Methods: We studied the association between selenium and risk of ESCC, EAC, and GCA within the prospective Netherlands Cohort Study, conducted among 120,852 men and women aged 55–69 years at baseline. In September 1986, the cohort members completed a questionnaire on risk factors for cancer and provided toenail clippings for determination of baseline selenium status. After 16.3 years of follow-up, 64 ESCC, 112 EAC, and 114 GCA cases and 2072 subcohort members with toenail selenium data were available for case-cohort analysis. Incidence rate ratios (RR) were calculated using Cox proportional hazards models. Results: In multivariable analyses of selenium status, we found an inverse association with ESCC (RR quartile 4 versus quartile 1 0.37, 95% confidence intervals (CI) 0.16–0.86), and a borderline significant inverse association with GCA (RR 0.52, 95% CI 0.27–1.02). No overall association was observed for EAC (RR 0.76, 95% CI 0.41–1.40), although results suggested an inverse association in women. Stratified analyses showed stronger associations in never smokers, and (only for EAC) in subjects with a low antioxidant intake. Conclusions: This prospective study supports an inverse association between toenail selenium and risk of ESCC and GCA and suggests an inverse association with risk of EAC in subgroups (women, never smokers, and low antioxidant consumers). These associations need confirmation. Citation Information: Cancer Prev Res 2010;3(1 Suppl):A113.
- Research Article
- 10.1158/1538-7445.am2019-1588
- Jul 1, 2019
- Cancer Research
Incidence of esophageal adenocarcinoma (EA) has risen substantially in Western countries over recent decades. Established risk factors for EA and its precursor lesion, Barrett’s esophagus (BE), include reflux, obesity, and tobacco smoking. Inherited genetic variation also influences disease risk, although only a limited number of susceptibility loci have been identified. Genomic analyses of EA tumors have revealed a distinctive mutational signature, high mutational burden, and extensive somatic chromosome alterations, features also observed in high-risk BE tissue. To explore whether germline variation in DNA repair-related genes may be associated with altered disease susceptibility, we analyzed data from a recent meta-analysis of genome-wide association studies (GWAS) encompassing 4,112 EA cases, 6,167 BE cases, and 17,159 controls, representing the largest sample size assembled for these conditions. Using a gene-based testing approach (VEGAS2), we assessed 263 DNA repair-related genes and found that variation in NEIL2, a mediator of base excision repair (BER), was significantly associated with risk of BE (P=1.4×10-5, q&lt;0.05). No other gene-level associations with BE or EA survived correction for multiple comparisons. SNP-level analysis of 239 polymorphisms at the NEIL2 locus revealed six variants strongly associated with altered risk of BE (P&lt;5×10-5, q&lt;0.01), with the index SNP classified as an intronic eQTL for NEIL2 in esophageal tissue. Four of these SNPs were also associated with risk of EA (P&lt;0.05), with odds ratios in the same direction and of similar magnitude. Our results provide evidence that germline genetic variation in a DNA glycosylase enzyme (NEIL2) may influence risk of BE/EA, and suggest a potential novel biological role for altered BER in BE/EA pathogenesis. Citation Format: Matthew F. Buas, Li Yan, Xuan Peng, Qianya Qi, Jianhong Chen, Aaron Thrift, Qianchuan He, Lynn Onstad, Puya Gharahkhani, Stuart MacGregor, Thomas L. Vaughan, Margaret M. Madeleine. Germline variation in DNA repair genes and risk of Barrett's esophagus and esophageal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1588.
- Conference Article
- 10.1158/1538-7445.sabcs18-1588
- Jul 1, 2019
Incidence of esophageal adenocarcinoma (EA) has risen substantially in Western countries over recent decades. Established risk factors for EA and its precursor lesion, Barrett’s esophagus (BE), include reflux, obesity, and tobacco smoking. Inherited genetic variation also influences disease risk, although only a limited number of susceptibility loci have been identified. Genomic analyses of EA tumors have revealed a distinctive mutational signature, high mutational burden, and extensive somatic chromosome alterations, features also observed in high-risk BE tissue. To explore whether germline variation in DNA repair-related genes may be associated with altered disease susceptibility, we analyzed data from a recent meta-analysis of genome-wide association studies (GWAS) encompassing 4,112 EA cases, 6,167 BE cases, and 17,159 controls, representing the largest sample size assembled for these conditions. Using a gene-based testing approach (VEGAS2), we assessed 263 DNA repair-related genes and found that variation in NEIL2 , a mediator of base excision repair (BER), was significantly associated with risk of BE (P=1.4×10 -5 , q NEIL2 locus revealed six variants strongly associated with altered risk of BE (P -5 , q NEIL2 in esophageal tissue. Four of these SNPs were also associated with risk of EA (P NEIL2 ) may influence risk of BE/EA, and suggest a potential novel biological role for altered BER in BE/EA pathogenesis. Citation Format: Matthew F. Buas, Li Yan, Xuan Peng, Qianya Qi, Jianhong Chen, Aaron Thrift, Qianchuan He, Lynn Onstad, Puya Gharahkhani, Stuart MacGregor, Thomas L. Vaughan, Margaret M. Madeleine. Germline variation in DNA repair genes and risk of Barrett9s esophagus and esophageal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1588.
- Front Matter
22
- 10.1053/j.gastro.2009.02.021
- Feb 23, 2009
- Gastroenterology
Alcohol Drinking and the Risk of Barrett's Esophagus and Esophageal Adenocarcinoma
- Preprint Article
- 10.1158/1055-9965.28918725
- May 2, 2025
<p>Supplementary Figure 1. Associations of esophageal adenocarcinoma risk per quantile increase in circulating novel biomarkers in the Department of Defense Serum Repository. Odd ratios (ORs) adjusted for matching variables, marital status and education. (A) displays ORs for the biomarkers in the Inflammation Panel, (B) displays ORs for the biomarkers in the Oncology II Panel, and (C) displays ORs for the biomarkers in the Cardiovascular III Panel.</p>
- Preprint Article
- 10.1158/1055-9965.28918713
- May 2, 2025
<p>Supplementary Table 3. Spearman's correlation coefficents among candidate biomarkers in Department of Defense Serum Repository.</p>
- Preprint Article
- 10.1158/1055-9965.28918719
- May 2, 2025
<p>Supplementary Table 1. Performance characteristics of measurement of 276 inflammation (blue), oncology (red) and cardiovascular (black) biomarkers in the Department of Defense Serum Repository.</p>
- New
- Research Article
- 10.1158/1055-9965.epi-25-1084
- Nov 6, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-1022
- Nov 5, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0123
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0617
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-1058
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0640
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0698
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0510
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0653
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- New
- Research Article
- 10.1158/1055-9965.epi-25-0712
- Nov 3, 2025
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.